BC Extra | Mar 5, 2019
Financial News

Secura Bio closes $145M financing

Oncology company Secura Bio said Tuesday it closed a $145 million financing led by Athyrium Capital. Athyrium and the executive team of Secura Bio Inc. (Henderson, Nev.) provided the $55 million equity portion of the...
BC Extra | Apr 18, 2017
Company News

Ionis, Ribo in China partnership

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it granted Suzhou Ribo Life Science Co. Ltd. (Kushan, China) Chinese commercialization rights to two antisense drug candidates in metabolic disease and cancer, with an option for a third candidate....
BC Week In Review | Mar 31, 2014
Company News

Bionamics GmbH, Evotec deal

Evotec acquired asset management company Bionamics for an undisclosed amount in cash. Bionamics will be eligible for undisclosed milestones. Bionamics focuses on translating academic innovations to assets for the biotech and pharma industry and manages...
BC Week In Review | Jul 1, 2013
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany   Business: Cardiovascular, Neurology   Date completed: 6/24/13   Type: Venture financing   Raised: €5 million ($6.6 million)   Investors: HeidelbergCapital; Entrepreneurs Fund; Bayern Kapital; Hanseatic Asset Management; company director  ...
BC Week In Review | Apr 6, 2009
Company News

Medac, Hannover Medical School deal

The school granted Medac exclusive, worldwide rights to develop and commercialize a test to diagnose the spread of acute lymphoblastic leukemia (ALL) to the central nervous system. The diagnostic, which is currently in clinical development,...
BC Week In Review | Mar 23, 2009
Company News

Inverness, Acon Laboratories Inc. deal

Inverness will acquire the remainder of Acon's rapid diagnostics business that it does not already own for about $200 million. The deal gives Inverness Acon's lateral flow immunoassay diagnostic products in China, Asia-Pacific, Latin America,...
BC Week In Review | Mar 2, 2009
Company News

Mbiotec, Helmholtz Center for Infection Research deal

MBiotec received exclusive, worldwide rights to develop and commercialize the center's MALP-2S and its derivatives to treat cancer. The synthetic analog of MALP-2, a lipopeptide from Mycoplasma fermentas has completed a Phase I/II trial to...
BC Week In Review | Jul 7, 2008
Company News

Ascenion GmbH, Protectimmun GmbH deal

Asset management company Ascenion received an undisclosed, single-digit equity stake in Protectimmun in exchange for past and ongoing consulting services and the negotiation of undisclosed licensing agreements. Protectimmun, which was founded in March 2007, has...
BC Week In Review | Dec 17, 2007
Company News

AmVac, Ascension GmbH, Helmholtz Center for Infection Research, Max Planck Society deal

AmVac received an exclusive, worldwide license to develop and commercialize vaccines using a modified non-replicating Sendai virus from Max Planck Innovation GmbH, the society's technology transfer agency. Max Planck Innovation will receive an upfront payment...
BioCentury | Dec 6, 2004
Finance

Ebb & Flow

Companies and bankers are starting to think that an IPO window will open in Europe next year, and a few companies are starting to prepare for the blessed event. U.K.-based endocrine and musculoskeletal company ProStrakan...
Items per page:
1 - 10 of 10
BC Extra | Mar 5, 2019
Financial News

Secura Bio closes $145M financing

Oncology company Secura Bio said Tuesday it closed a $145 million financing led by Athyrium Capital. Athyrium and the executive team of Secura Bio Inc. (Henderson, Nev.) provided the $55 million equity portion of the...
BC Extra | Apr 18, 2017
Company News

Ionis, Ribo in China partnership

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it granted Suzhou Ribo Life Science Co. Ltd. (Kushan, China) Chinese commercialization rights to two antisense drug candidates in metabolic disease and cancer, with an option for a third candidate....
BC Week In Review | Mar 31, 2014
Company News

Bionamics GmbH, Evotec deal

Evotec acquired asset management company Bionamics for an undisclosed amount in cash. Bionamics will be eligible for undisclosed milestones. Bionamics focuses on translating academic innovations to assets for the biotech and pharma industry and manages...
BC Week In Review | Jul 1, 2013
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany   Business: Cardiovascular, Neurology   Date completed: 6/24/13   Type: Venture financing   Raised: €5 million ($6.6 million)   Investors: HeidelbergCapital; Entrepreneurs Fund; Bayern Kapital; Hanseatic Asset Management; company director  ...
BC Week In Review | Apr 6, 2009
Company News

Medac, Hannover Medical School deal

The school granted Medac exclusive, worldwide rights to develop and commercialize a test to diagnose the spread of acute lymphoblastic leukemia (ALL) to the central nervous system. The diagnostic, which is currently in clinical development,...
BC Week In Review | Mar 23, 2009
Company News

Inverness, Acon Laboratories Inc. deal

Inverness will acquire the remainder of Acon's rapid diagnostics business that it does not already own for about $200 million. The deal gives Inverness Acon's lateral flow immunoassay diagnostic products in China, Asia-Pacific, Latin America,...
BC Week In Review | Mar 2, 2009
Company News

Mbiotec, Helmholtz Center for Infection Research deal

MBiotec received exclusive, worldwide rights to develop and commercialize the center's MALP-2S and its derivatives to treat cancer. The synthetic analog of MALP-2, a lipopeptide from Mycoplasma fermentas has completed a Phase I/II trial to...
BC Week In Review | Jul 7, 2008
Company News

Ascenion GmbH, Protectimmun GmbH deal

Asset management company Ascenion received an undisclosed, single-digit equity stake in Protectimmun in exchange for past and ongoing consulting services and the negotiation of undisclosed licensing agreements. Protectimmun, which was founded in March 2007, has...
BC Week In Review | Dec 17, 2007
Company News

AmVac, Ascension GmbH, Helmholtz Center for Infection Research, Max Planck Society deal

AmVac received an exclusive, worldwide license to develop and commercialize vaccines using a modified non-replicating Sendai virus from Max Planck Innovation GmbH, the society's technology transfer agency. Max Planck Innovation will receive an upfront payment...
BioCentury | Dec 6, 2004
Finance

Ebb & Flow

Companies and bankers are starting to think that an IPO window will open in Europe next year, and a few companies are starting to prepare for the blessed event. U.K.-based endocrine and musculoskeletal company ProStrakan...
Items per page:
1 - 10 of 10